The Global Human Chorionic Gonadotropin (hCG) Market was valued at USD 1.12 Billion in 2024 and is projected to reach USD 1.68 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period (2024–2030). This robust growth is primarily driven by the rising global prevalence of infertility, increasing demand for assisted reproductive technologies (ART), and expanding therapeutic applications in hormone-related disorders.

As the healthcare and pharmaceutical industries continue to innovate in reproductive medicine and hormonal therapies, the focus intensifies on the key manufacturers and suppliers who are pioneering advanced hCG-based treatments. In this blog, we profile the Top 10 Companies in the Human Chorionic Gonadotropin Industry—a blend of pharmaceutical giants, specialized biotech firms, and biosimilar developers shaping the future of fertility and therapeutic care.

---

🔟 1. Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: Pregnyl® (Chorionic Gonadotropin for Injection, USP)

Merck & Co. is a leading global pharmaceutical company with a significant presence in the women’s health and fertility sector. Its flagship hCG product, Pregnyl®, is a highly purified preparation used for the induction of ovulation and pregnancy in anovulatory, infertile women, and for the treatment of hypogonadism in men.

Innovation and Development Focus:

• Ongoing clinical research to expand indications for Pregnyl®

• Strategic focus on enhancing its reproductive medicine portfolio

• Investment in advanced manufacturing processes for biologic consistency

Download FREE Sample Report: Human Chorionic Gonadotropin Market – View in Detailed Research Report

---

9️⃣ 2. Ferring Pharmaceuticals

Headquarters: Saint-Prex, Switzerland
Key Offering: Ovidrel® / Ovitrelle® (recombinant hCG)

Ferring Pharmaceuticals is a specialist in reproductive medicine and women’s health. The company’s recombinant hCG product, Ovidrel®/Ovitrelle®, is a key asset in its portfolio, widely used for final follicular maturation and luteinization in women undergoing superovulation as part of an ART cycle.

Innovation and Development Focus:

• Pioneering recombinant technology for higher purity hCG

• Dedicated R&D in personalized fertility treatments

---

8️⃣ 3. Fresenius Kabi

Headquarters: Bad Homburg, Germany
Key Offering: hCG Active Pharmaceutical Ingredient (API) and finished formulations

Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. It is a significant supplier of hCG, both as an Active Pharmaceutical Ingredient (API) to other manufacturers and in its own branded and generic formulations, supplying markets worldwide.

Innovation and Development Focus:

• Expansion of its biosimilars portfolio, including hCG

• Focus on cost-effective manufacturing to improve accessibility

---

7️⃣ 4. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, India
Key Offering: Generic hCG formulations (e.g., C-Gonin, HCG CP Injection)

As one of the world’s largest specialty generic pharmaceutical companies, Sun Pharma has a strong portfolio that includes hormonal products. The company manufactures and markets several hCG-based formulations, making these critical treatments more accessible, particularly in cost-sensitive markets across Asia, Latin America, and Africa.

Innovation and Development Focus:

• Development of novel delivery systems for hCG

• Strategic acquisitions to strengthen its global hormone therapy footprint

Download FREE Sample Report: Human Chorionic Gonadotropin Market – View in Detailed Research Report

---

6️⃣ 5. Livzon Pharmaceutical Group Inc.

Headquarters: Zhuhai, China
Key Offering: Lizu® (Urinary-derived hCG)

Livzon is a leading Chinese pharmaceutical manufacturer with a dominant position in the domestic hCG market. Its product, Lizu®, is a urinary-derived human chorionic gonadotropin widely used in fertility treatments across China and other emerging markets. The company benefits from a vast domestic market and growing healthcare expenditure.

Innovation and Development Focus:

• Investing in upgrading its biologic manufacturing facilities

• Expanding international regulatory approvals for its hCG products

---

5️⃣ 6. Bristol Myers Squibb (Previously part of Celgene portfolio)

Headquarters: New York, New York, USA
Key Offering: Historical involvement through legacy products

While Bristol Myers Squibb’s current primary focus is on oncology and immunology, its portfolio includes legacy assets and expertise from acquisitions, such as Celgene. The company’s vast experience in complex biologics manufacturing gives it a foundational understanding relevant to the hCG market landscape.

Innovation and Development Focus:

• Strategic focus remains on core therapeutic areas (oncology, immunology)

• World-class R&D infrastructure applicable to biologic development

---

4️⃣ 7. Emd Serono (Merck KGaA, Darmstadt, Germany)

Headquarters: Darmstadt, Germany (Global), Rockland, Massachusetts, USA (EMD Serono)
Key Offering: Gonal-f® (rFSH), with complementary role in fertility treatment cycles often involving hCG

EMD Serono, the North American biopharma business of Merck KGaA, Darmstadt, Germany, is a powerhouse in fertility treatments. While renowned for Gonal-f®, its gonadotropin portfolio is central to ART protocols that routinely include hCG for triggering ovulation, positioning the company as a key influencer in the hCG ecosystem.

Innovation and Development Focus:

• Leadership in recombinant technology for fertility hormones

• Integrated fertility solutions combining multiple gonadotropins

---

3️⃣ 8. Sanzyme Biologics (Previously Bharat Biotech)

Headquarters: Hyderabad, India
Key Offering: ZyHCG® (Recombinant hCG), urinary hCG

Sanzyme Biologics is a specialist in microbial fermentation and a leading producer of recombinant proteins, including hCG. The company’s ZyHCG® is one of the early recombinant hCG offerings, providing a high-purity alternative to urinary-derived products, and is supplied to pharmaceutical companies globally.

Innovation and Development Focus:

• Expertise in cost-effective recombinant manufacturing

• Focus on supplying hCG API to global and regional pharma companies

---

2️⃣ 9. Bioprofarma

Headquarters: Lisburn, United Kingdom
Key Offering: Choragon® (hCG injection)

Bioprofarma, part of the Gedeon Richter group, is a dedicated manufacturer of infertility treatments. Its product, Choragon®, is a well-established urinary-derived hCG used extensively in European and international markets for triggering final follicular maturation in ART cycles.

Innovation and Development Focus:

• Specialization in high-purity urinary gonadotropins

• Strengthening distribution networks in emerging markets

---

1️⃣ 10. Bharat Serums and Vaccines Ltd. (BSV)

Headquarters: Mumbai, India
Key Offering: Ovutrig (hCG for Injection)

Bharat Serums and Vaccines is a prominent Indian biopharmaceutical company with a strong portfolio in critical care, gynecology, and fertility. Its hCG product, Ovutrig, is a key player in the Indian subcontinent and other price-sensitive markets, offering a reliable and affordable option for fertility treatment.

Innovation and Development Focus:

• Expanding its biologics manufacturing capabilities

• Leveraging strong domestic presence to capture growing ART demand

Get Full Report Here: Human Chorionic Gonadotropin Market – View in Detailed Research Report

---

🔬 Outlook: The Future of hCG is Precision and Personalization

The Human Chorionic Gonadotropin market is experiencing a significant evolution. While traditional urinary-derived hCG remains vital, the industry is increasingly shifting towards recombinant technologies for improved purity and consistency, alongside exploring novel formulations and delivery methods.

📈 Key Trends Shaping the Market:

• Rising adoption of recombinant hCG over urinary-derived products

• Growth in ART cycles globally, particularly in Asia-Pacific and Latin America

• Increasing research into hCG’s therapeutic potential beyond fertility (e.g., weight loss, hypogonadism)

• Expansion of biosimilar hCG products, driving competition and affordability

Get Full Report Here: Human Chorionic Gonadotropin Market – View in Detailed Research Report

The companies listed above are not only supplying essential therapeutics—they’re pioneering the next generation of reproductive healthcare solutions.